DBV Technologies S.A. 8-K

What Happened

• On June 29, 2026, DBV Technologies S.A. filed a Form 8-K (Item 8.01) and issued a press release titled “DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 Through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing.” The company said it is working with the U.S. Food and Drug Administration (FDA) to optimize the review process as it prepares a Biologics License Application (BLA) filing for the VIASKIN® Peanut Patch for children aged 4 through 7.

Key Details

• Filing date: June 29, 2026 (Form 8-K, Item 8.01).
• Program: BLA submission update for VIASKIN® Peanut Patch targeting children aged 4–7 years.
• Regulatory: Company is collaborating with the FDA to optimize the review process ahead of the BLA filing.
• Exhibit: Press release attached as Exhibit 99.1 to the Form 8-K.

Why It Matters

• This update signals regulatory progress for DBV’s lead product candidate; working directly with the FDA can affect the timing and efficiency of the BLA submission and review.
• For investors, progress toward a BLA filing is a material development because FDA decisions and filing timelines can materially impact DBV’s future commercial prospects and valuation.
• The filing contains no new financial results or commitments; it is a disclosure of a regulatory update and ongoing engagement with the FDA.